

Form PTO-892 U.S. Department of Commerce		Serial Number 09/756,411	Group Art Unit 1623	Attachment to Paper Number 03162004	
Notice of References Cited		APPLICANT(S) Lori et al.			

U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	A	4,708,818 A	11/24/87	Montagnier et al.	435	005.000	
*	B	5,026,687 A	06/25/91	Yarchoan et al.	514	045.000	
*	C	5,110,600 A	05/05/92	Green	424	450.000	
*	D	5,300,059 A	04/05/94	Rubinstein et al.	604	408.000	
*	E	5,521,161 A	05/28/96	Malley et al. (I)	514	045.000	
*	F	5,736,526 A	04/07/98	Malley et al. (II)	514	045.000	
*	G	5,736,527 A	04/07/98	Malley et al. (III)	514	045.000	
*	H	6,046,175 A	04/04/20	Lori et al. (I)	514	045.000	
*	I	6,093,702 A	07/25/00	Malley et al. (IV)	514	045.000	
*	J	6,194,390 B1	02/27/01	Lori et al. (II)	514	045.000	
*	K	6,093,702 A	07/25/00	Malley et al. (V)	514	045.000	

Foreign Patent Documents

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS	
*	L	EP 0,206,497 A2	12/30/86	Europe(EPO)	Wellcome Fndtn	-----	-----	
*	M	WO 87/01284 A1	03/12/87	World(WO/PCT)	US Dept. Commerce	-----	-----	

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

* R	Gao et al. (I), "Low Levels of Deoxynucleotides in Peripheral Blood Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1 Replication," Proc. National Academy Sciences USA, 90, 8925-8928 (October, 1993).
------------	---

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. E. Crane	DATE 03/16/04	page 1 of 5
¥: Reference not presently available.		
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892
U.S. Department of Commerce

Serial Number Group Art Unit
09/756,411 **1623** Attachment to Paper Number
03162004

Notice of References Cited

APPLICANT(S)

Lori et al.

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

* S†	<u>Biochemicals/Organic Compounds for Research and Diagnostic Reagents, Sigma Chemical Co.</u> (catalog), St. Louis, MO, 1992, pp. 321, 341-342.
* T†	Fedorino et al. , "Prevention of Activation of HIV-1 by Antiviral Agents in OM-10.1 Cells," <i>Antiviral Chemistry & Chemotherapy</i> , 4(1), 55-63 (1993).
* U†	Snyder et al. (I) , "Effects of Hydroxyurea and Thymidine Derivatives on the Uptake and Metabolism of Deoxycytidine and Arabinosylcytosine in Log Phase and Contact-Inhibited Human Fibroblasts," <i>Molecular Pharmacology</i> , 28(6), 574-580 (1985); see p. 578 in particular.
* V	Licastro et al. , "Inhibition of Polymerases- α and - β Completely Blocks DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells," <i>Biochemical Biophysical Res. Comm.</i> , 132(3), 929-933 (Nov. 15, 1985).
* W†	Busso et al. , "Cellular Pharmacology and Anti-HIV Activity of 2',3'-Dideoxyguanosine," <i>AIDS Res. Human Retroviruses</i> , 6(9), 1139-1146 (1990).
* X	R. S. Root-Bernstein (I) , "AIDS IS More Than HIV: Part I," <i>Genetic Engineering News</i> , September 1, 1992, pp. 4-6.
* Y	R. S. Root-Bernstein (II) , "AIDS IS More Than HIV: Part II," <i>Genetic Engineering News</i> , September 15, 1992, pp. 4-5.
* Z	"Kaposi's Sarcoma and <i>Pneumocystis</i> Pneumonia Among Homosexual Men," <u>Morbidity Mortality Weekly Rept.</u> , Vol. 30(25), Centers for Disease Control , July 3, 1981, pp. 305-308.

† Month of publication date is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.


EXAMINER L. E. Crane	DATE 03/16/04	page 2 of 5
¥: Reference not presently available.		
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number 09/756,411	Group Art Unit 1623	Attachment to Paper Number 03162004	
Notice of References Cited	APPLICANT(S) Lori et al.			

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

* RA [†]	Barre-Sinoussi et al. , "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)," <i>Science</i> , 220, 868-871 (1983).
* SA	Fauci (I) , "The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis," <i>Science</i> , 239, 617-622 (February 1988).
* TA	Fauci (II) , "Multifactoral Nature of Human Immunodeficiency Virus Disease: Implications for Therapy," <i>Science</i> , 262, 1011-1018 (November 12, 1993).
* UA	Zack et al. , "HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure," <i>Cell</i> , 61, 213-222 (April 20, 1990).
* VA	Bukrinsky et al. , "Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection," <i>Science</i> , 254, 233-237 (October 18, 1991).
* WA	Schnittman et al. , "The Reservoir for HIV-1 in Human Peripheral Blood Is a T Cell that Maintains Expression of CD4," <i>Science</i> , 245, 305-308 (July, 1989).
* XA	Fox et al. , "Lymphoid Germinal Centers Are Reservoirs of Human Immunodeficiency Virus Type 1 RNA," <i>Journal of Infectious Diseases</i> , 164, 1051-1057 (December, 1991).
* YA	Hirsch et al. , "Therapy for Human Immunodeficiency Virus Infection," <i>New England Journal of Medicine</i> , 328(23), 1686-1695 (June 10, 1993).

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.


EXAMINER L. E. Crane 	DATE 03/16/04	page 3 of 5
¥: Reference not presently available.		
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number 09/756,411	Group Art Unit 1623	Attachment to Paper Number 03162004	
Notice of References Cited	APPLICANT(S) Lori et al.			

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

* ZA†	Pauwels et al., "Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds," <i>Journal of Virological Methods</i> , 20, 309-321 (1988).
* RB	Yarchoan et al., "Clinical Pharmacology of 3'-Azido-2', 3'-dideoxythymidine (Zidovudine) and Related Dideoxynucleosides," <i>New England Journal of Medicine</i> , 321(11), 726-738 (September 14, 1989).
* SB†	Chow et al., "Use of Evolutionary Limitations of HIV-1 Multidrug Resistance to Optimize Therapy," <i>Nature</i> , 361, 650-654 (1993).
* TB	Lori et al.(III), "Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication," <i>Science</i> , 266, 801-805 (November 4, 1994).
* UB†	Karlsson et al., "Hydroxyurea Increases the Phosphorylation of 3'-fluorothymidine and 3'-Azidothymidine in CEM Cells," <i>European Journal of Biochemistry</i> , 186, 689-694 (1989).
* VB†	Marquez et al., "Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV," <i>Journal of Medicinal Chemistry</i> , 33(3), 978-985 (1990).
* WB†	Snyder et al. (II), "The Accumulation of DNA Breaks Due to Incision; Comparative Studies with Various Inhibitors," Ch. 2 in <u>DNA Repaiet al. r and Its Inhibition</u> , <u>Nucleic Acids Symposium Series No. 13</u> , Collins et al. eds., IRL Press, Oxford, England, 1984, pp. 13-33.

† Month of publication date is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. E. Crane 	DATE 03/16/04	page 4 of 5
¥: Reference not presently available.		
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892
U.S. Department of Commerce

Serial Number

09/756,411

Group Art
Unit

1623

Attachment to
Paper Number

03162004

Notice of References Cited

APPLICANT(S)


Lori et al.

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

* XB	Vila et al., "Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine [ddI] and Hydroxycarbamide [aka Hydroxyurea]," <i>Lancet</i> , 350(9078), 635-636 (August 30, 1997).
* YB	Schoofs, "The Berlin Patient," <i>The New York Times Magazine</i> , pp. 32-35, June 21, 1998.
* ZB†	Balzarini, J., "Effect of Antimetabolite Drugs of Nucleotide Metabolism on the Anti-Human Immunodeficiency Virus Activity of Nucleoside Reverse Transcriptase Inhibitors," <i>Pharmacology and Therapeutics</i> , 87(2-3), 175-187 (2000).††
* RC†	Gao et al. (II), "Enhancement by Hydroxyurea of the Anti-Human Immunodeficiency Virus Type 1 Potency of 2'-β-Fluoro-2',3'-dideoxyadenosine in Peripheral Blood Mononuclear Cells," <i>Biochemical Pharmacology</i> , 50(2), 274-276 (1995).††
* SC†	Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine," <i>Molecular Pharmacology</i> , 37, 590-596 (1990).
TC†	Hitchcock et al., "Biochemical Pharmacology of 2'-Fluoro-2',3'-dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and Chemical Stability over 2',3'-Dideoxyadenosine," <i>Antiviral Chemistry & Chemotherapy</i> , 1, 319-327 (1990).
* UC	Gao et al. (III), "Differential Phosphorylation of Azidothymidine, Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral Blood Mononuclear Cells," <i>Journal of Clinical Investigations</i> , 91(5), 2326-2333 (May, 1993).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Copy kindly supplied by Applicant.

EXAMINER 	DATE 03/16/04	page 5 of 5 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		